$0.643
-0.026 (-4.06%)At close
CNSY News
CNSY Events
Cerenome Presents Preclinical Data on REYOBIQ Showing Antitumor Activity
Cerenome announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ, its lead investigational targeted radiotherapeutic. In two mouse models of aggressive epithelial ovarian cancer, treatment with rhenium obisbemeda, the active agent in REYOBIQ, was associated with tumor injury and changes in the tumor microenvironment. Combination treatment with anti-PD-1 checkpoint blockade also showed improved antitumor activity, extending median survival to 65 days, longer than control or either agent alone. "Turning 'cold' or immunologically resistant tumors into 'hot' or immunologically responsive tumors is the major limitation for the broader use of checkpoint inhibitors," said Eric Daniels, chief development officer.
Related articles
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.